|Systematic (IUPAC) name|
|Mol. mass||562.14 g/mol|
|(what is this?)|
Indometacin farnesil (INN) is a prodrug of the non-steroidal anti-inflammatory drug indometacin, designed to reduce the occurrence of side-effects by esterification of the carboxyl group on indometacin with farnesol. Indometacin farnesil was first approved in Japan in 1991, and is available in Japan and Indonesia, under the trade names Infree and Dialon respectively.
|This drug article relating to the musculoskeletal system is a stub. You can help Wikipedia by expanding it.|